What is Amneal Pharmaceuticals, Inc.'s specialty — R&D?

Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — R&D of $5.99M in Q2 2026.

How has Amneal Pharmaceuticals, Inc.'s specialty — R&D changed year-over-year?

Amneal Pharmaceuticals, Inc.'s specialty — R&D decreased by 1.2% year-over-year, from $6.07M to $5.99M.

What does specialty — R&D mean?

Expenditures dedicated to the discovery, clinical development, and regulatory approval of new specialty pharmaceutical products. This investment is critical for long-term pipeline growth and sustaining the competitive advantage of the specialty portfolio.

Amneal Pharmaceuticals, Inc. (AMRX) Specialty — R&D

Screener

Other segment segments

Affordable Medicines

$33.02M-21.2%

AvKARE

$0—

Similar metrics at other companies

ACNTSpecialty Chemicals — R&D

$63K—

KLACSpecialty Semiconductor Process — R&D

$15.2M+17.7%

IAR

IARTSpecialty Surgery — R&D

$14.2M-2.9%

INSMARIKAYCE external R&D expenses — R&D

$6.23M-43.4%

INSMBrensocatib external R&D expenses — R&D

$13.83M-58.8%

INSMTPIP external R&D expenses — R&D

$38.94M+88.6%

Other financials

Income statement

See full

Revenue$796.2M+9.9%

Gross profit$334.5M+16.9%

Operating income$129.8M+16.5%

Net income$57.7M+157%

EPS (diluted)$0.18+157%

Balance sheet

See full

Cash & equivalents$127.6M+78.4%

Total debt$2.6B+18.0%

Total equity$33.0M+129%

Total assets$3.8B+10.3%

Cash flow

See full

Operating cash flow-$21.2M-125%

CapEx$30.7M+34.5%

Free cash flow-$51.9M-185%

Valuation

See full

Market cap$5.77B+129%

Enterprise value$8.21B+77.4%

P/E36.7×-711×

P/S1.9×+1.0×

Profitability

See full

Gross margin39.3%+1.7pp

Operating margin14.6%+1.4pp

Net margin5%+4.9pp

FCF margin4.1%-5.8pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity77.8×—

Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 5:19 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001723128-26-000031

Three Months Ended June 30, 2026	Affordable Medicines (1)	Specialty	Av KARE	Corporateand Other	Total Company
Cost of goods sold	282,684	48,265	130,740	—	461,689
Gross profit	207,229	101,030	26,249	—	334,508
Selling, general and administrative	42,367	40,095	16,913	49,347	148,722
Research and development	33,023	5,994	—	—	39,017
Intellectual property legal development expenses	2,002	85	—	—	2,087
Acquisition costs	—	—	—	7,600	7,600
Restructuring and other charges	—	—	—	554	554
Charges related to legal matters, net	8,057	—	—	—	8,057

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s specialty — R&D?: Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — R&D of $5.99M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — R&D changed year-over-year?: Amneal Pharmaceuticals, Inc.'s specialty — R&D decreased by 1.2% year-over-year, from $6.07M to $5.99M.
What does specialty — R&D mean?: Expenditures dedicated to the discovery, clinical development, and regulatory approval of new specialty pharmaceutical products. This investment is critical for long-term pipeline growth and sustaining the competitive advantage of the specialty portfolio.